Press Releases and Events
PRESS RELEASES
Press Release | October 21, 2021
Press Release | October 20, 2021
Crinetics Pharmaceuticals Announces Proposed Public Offering of Common Stock
READ MORE
Press Release | October 18, 2021
Radionetics Oncology Emerges from Crinetics Pharmaceuticals with a Platform and Deep Pipeline of Nonpeptide Targeted Radiopharmaceutical Drug Candidates for Precision Oncology
READ MORE
Press Release | September 27, 2021
Crinetics Pharmaceuticals Unveils Parathyroid Hormone Receptor Antagonist Program at ASBMR
READ MORE
Press Release | September 15, 2021
CRN04777 Demonstrates Pharmacologic Proof-of-Concept with Strong Dose-dependent Suppression of Insulin Secretion in Phase 1 Single Ascending Dose Study
READ MORE
Press Release | September 7, 2021
Crinetics Pharmaceuticals to Participate in September Investor Conferences
READ MORE
Press Release | September 2, 2021
Crinetics Appoints Jeff Knight as Chief Operating Officer
READ MORE
Press Release | August 10, 2021
Crinetics' Second Quarter 2021 Financial Results and Corporate Update
READ MORE
Press Release | August 10, 2021
CRN04894, Demonstrates Pharmacologic Proof-of-Concept with Strong Dose-Dependent Cortisol Suppression in Phase 1 Single Ascending Dose Study
READ MORE
Press Release | July 29, 2021
Crinetics Pharmaceuticals Announces $15.0 Million Private Placement with Frazier Healthcare Partners
READ MORE
SIGN UP
WEBCAST
PRESENTATIONTransforming Endocrine Disease Treatment
Be the first to know about the advances we're making in endocrine-rooted care.
Email Signup
You are now leaving Crinetics.com
Please click CONTINUE below to learn more about a new treatment option. This website contains information about a prescription medicine.
